The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CSBR | -4.37% | -36.72% | -8.74% | -40% |
| S&P | +16.49% | +84.25% | +12.99% | +1,557% |
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
No news articles found for Champions Oncology.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $15.04M | 11.5% |
| Gross Profit | $7.42M | 31.0% |
| Gross Margin | 49.32% | 7.3% |
| Market Cap | $94.31M | 77.4% |
| Market Cap / Employee | $442.78K | 0.0% |
| Employees | 213 | 1.4% |
| Net Income | $237.00K | -67.4% |
| EBITDA | $542.00K | -52.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.52M | 209.2% |
| Accounts Receivable | $11.54M | 10.2% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.79M | -31.3% |
| Short Term Debt | $1.62M | 4.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 9.00% | 11.2% |
| Return On Invested Capital | -31.46% | 16.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,977.00K | -424.4% |
| Operating Free Cash Flow | -$1,735.00K | -513.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 24.41 | 22.01 | 31.63 | 41.11 | - |
| Price to Book | 221.08 | 17.92 | 23.08 | 26.88 | -116.79% |
| Price to Sales | 2.69 | 1.73 | 1.53 | 1.69 | 65.45% |
| Price to Tangible Book Value | 435.12 | 19.09 | 25.33 | 29.72 | -137.30% |
| Price to Free Cash Flow TTM | 14.05 | 12.04 | 17.53 | - | |
| Enterprise Value to EBITDA | 32.95 | -71.88 | -555.57 | 176.84 | 238.30% |
| Free Cash Flow Yield | 7.1% | 8.3% | 5.7% | - | |
| Return on Equity | 376.8% | 503.0% | 185.9% | 102.7% | -166.49% |
| Total Debt | $6.70M | $6.33M | $5.93M | $5.41M | -23.44% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
